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The amyloid protein in Finnish hereditary amyloidosis is a fragment of the actin-filament binding region of a variant gelsolin molecule. Here we 
demonstrate, using polymerase chain reaction and allele-specific oligonucleotide hybridization analyses of genomic DNA, a single base mutation 
@Y4+Ads4) in the gelsolin gene segment encoding the amyloid protein. The mutation is responsible for the expression of the variant (Asn1a7) 
gelsolin molecule in Finnish hereditary amyloidosis. The nucleotide substitution was found in all five unrelated patients with Finnish amyloidosis 
studied, but not in 45 unrelated control subjects. The mutation co-segregated with the disease phenotype in a family with Finnish amyloidosis. 
The results show that a single substitution in the gelsolin gene causes Finnish hereditary amyloidosis. The allele-specific oligonucleotide hybridiza- 
tion method provides a simple and accurate means of detecting this mutation. 
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1. INTRODUCTION 2. METHODS 
Finnish hereditary amyloidosis (McKusick No. 
105120; familial amyloidosis, Finnish type; Meretoja 
amyloidosis) constitutes a clinically and biochemically 
distinct entity among the autosomal dominant amyloid 
polyneuropathy syndromes [l]. It is characterized by 
lattice cornea1 dystrophy, progressive cranial 
neuropathy and systemic amyloid deposits [2,3]. We 
have demonstrated that the amyloid protein in Finnish 
hereditary amyloidosis represents a novel type that 
shows amino acid homology with the actin-modulating 
protein gelsolin [4]. The gelsolin-nature of the amyloid 
was confirmed by others [5]. Our recent studies show 
that the amyloid protein is derived from an Asp18’ Asn 
mutant of gelsolin [6,7]. Based on this substitution and 
the gelsolin cDNA sequence [8,9] we predicted that a 
single base mutation (G6s4+ A654) in genomic DNA 
would be responsible for the protein variant. To 
demonstrate this mutation we amplified the target DNA 
with polymerase chain reaction for oligonucleotide 
hybridization analyses. The G654-+ A654 nucleotide 
substitution in the gelsolin gene was found in all studied 
patients with Finnish hereditary amyloidosis, but in 
none of the control subjects. The co-segregation of the 
mutation and the disease phenotype in a family with 
Finnish hereditary amyloidosis is also shown. 
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2. I. Samples and DNA extraction 
Blood samples were collected from 5 unrelated patients with Fin- 
nish hereditary amyloidosis, 9 family members of one of the patients, 
and 45 healthy unrelated individuals. DNA was extracted from white 
blood cells using a standard detergent lysis and proteinase K digestion 
protocol, and purified by phenol extraction and ethanol precipitation 
[lo]. 200-400 ng genomic DNA was used for each polymerase chain 
reaction. 
2.2. Polymerase chain reaction (PCR) for gelsolin 
Primers flanking the predicted mutated region were designed ac- 
cording to a published plasma gelsolin sequence [8]. The following 
primers were used (5 ’ to 3 ‘): TCC TGG GAG AGC TTC AAC AAT 
GGC (forward) and GTT GCC CAG GTC CAG GAT GAA GCA 
(reverse). The PCR [l l] program was 94°C for 1.2 mitt, 55°C for 1.0 
min, and 72°C for 1 .O min for 30 cycles. The reaction was in 50 mM 
KCI, 10 mM Tris pH 9.0, 1 mM MgClr, and 0.01% gelatin with 2 units 
of Cetus Taq polymerase in a final volume of 100 ~1. The PCR pro- 
ducts were analyzed by electrophoresis n 3% agarose gels containing 
0.5 pg/ml ethidium bromide. 
2.3. Oligonucleotide hybridization 
Ten ~1 of each polymerase chain reaction was heated to 95°C to 
denature DNA and dotted on nylon filters (Zeta-Probe, Bio-Rad, 
Richmond, California). The filters were ultraviolet irradiated to 
crosslink DNA. Prehybridization and hybridization were in 1 mM 
EDTA, 0.5 M NaHrP04 pH 7.2, 7% SDS at 62°C. Oligonudeotides 
specific for the normal plasma gelsolin sequence (AAC AAT GGC 
GAC TGC TTC ATC) or the predicted mutation sequence (AAC 
AAT GGC AAC TGC TTC ATC) were end-labelled with “P using - 
the kinase reaction [12] and hybridized to the filters. Filters were 
washed at high stringency at 62°C and autoradiographed overnight 
with an intensifying screen. 
3. RESULTS 
3. I. Polymerase chain reaction and oligonucleotide 
hybridization 
The PCR products were analyzed by electrophoresis. 
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was less intense in the 5 patient samples (Fig. 1A). The 
oligonucleotide containing the predicted G to A change 
hybridized under the same conditions to the 5 patient 
samples but not to any of the normal controls (Fig. 1B). 
In further experiments, hybridization to the normal 
oligonucleotide but not to the mutation sequence was 
observed in altogether 45 unrelated healthy individuals. 
December 1990 
Fig. 1. Oligonucleotide hybridization to amplified DNA samples. (A) 
a 21 bp oligonucleotide corresponding to the normal plasma gelsolin 
sequence hybridizes to both patient (Pl-P5) and control (Cl-CS) 
samples. Note the weaker signal with patient DNA (heterozygous) 
compared with control DNA (homozygous, normal). (B) a 21 bp 
oligonucleotide with the single base G-A change hybridizes to 
patient samples (PI-P5) but not to control samples (Cl-C5). The 
hybridization and washes were under the same conditions at 62°C for 
both oligonucleotides. 
A single fluorescent band was visible under ultraviolet 
light, corresponding in size to the expected 5 1 bp reac- 
tion product [8]. Filters containing 10 ~1 amplified 
DNA from 5 unrelated patients and 5 healthy in- 
dividuals were hybridized to end-labelled oligo- 
nucleotides specific for the normal sequence or the 
predicted mutation. The oligonucleotide with the nor- 
mal sequence hybridized to all samples, but the signal 
3.2. Family study 
Samples from a family with Finnish hereditary 
amyloidosis were analyzed for the mutation. The 
pedigree and the results for oligonucleotide hybridiza- 
tion are shown in Fig. 2. The mutant gene was found in 
all members with clinical symptoms of the disease, One 
family member (no 13), a 26-year-old woman, was 
found to have the mutation without having disease 
manifestations. She apparently represents a presymp- 
tomatic gene carrier. 
4. DISCUSSION 
This study shows that in Finnish hereditary 
amyloidosis the gelsolin gene, located on chromosome 
9 [9], contains a single base mutation G654 + A654 in the 
DNA segment encoding the amyloid protein. This 
mutation is responsible for the expression of the variant 
Asp”’ Asn gelsolin molecule which is the precursor of 
the amyloid subunit protein in Finnish hereditary 
amyloidosis [6,7]. The mutation was demonstrated in 
all patients, but in none of the 45 unrelated Finnish con- 
trol subjects. In the family study, the mutant gene was 
demonstrated in all members with clinical symptoms of 
the disease, as well as in one asymptomatic family 
member apparently representing a presymptomatic 
gene carrier. This is the first demonstration of a human 
disease linked to a single base mutation in the gelsolin 
gene. Recently, the torsion dystonia gene has been 
shown to be linked to the gelsolin gene [13], but the 
pathogenetic significance of this association is unclear. 
Fig. 2. Pedigree of a family with Finnish hereditary amyloidosis in 3 generations. The results of oligonucleotide hybridizations are given for each 
individual studied. G, normal allele; A, mutated allele. Clinically affected individuals are indicated by solid symbols. The arrow indicates the 
proband. Cases 1, 2, 7 (deceased) and 10 were not examined. Circles, females; squares, males. 
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By the end of the 1970’s more than 300 cases of 
hereditary amyloidosis characterized by lattice cornea1 
dystrophy and cranial neuropathy had been recorded in 
Finland [ 141. The disease shows strong geographic 
isolation; individuals in the neighbouring districts in 
Southern Finland, South Hame and Kymenlaakso, 
have been known to be affected at least since the 17th 
century. It has been suggested that the mutation occur- 
red or was introduced in this region at least 500 years 
ago [3]. The disease is, however, not limited to Finland. 
Cases have also been described from the United States 
[15-171, Denmark [18] and the Netherlands [19]. It re- 
mains to be determined what mutations cause the 
disease in other populations than the Finns. 
The disease is inherited in an autosomal dominant 
fashion. In heterozygous patients, the disease has a late 
onset and is slowly progressive. By the age of 20 years, 
cornea1 dystrophy is usually manifested and by the age 
of 40 years most patients have developed cranial 
neuropathy. Skin, renal and cardiac manifestations also 
occur. In the rare presumptively homozygous subjects, 
the disease has a more severe clinical course characteriz- 
ed by renal insufficiency and a life-expectancy of about 
30 years [3]. The demonstration of a base mutation in 
the gelsolin gene and its association with the amyloid 
disease now opens a new approach for the accurate 
diagnosis of Finnish hereditary amyloidosis. By use of 
the polymerase chain reaction the DNA segment can be 
amplified and the mutation easily demonstrated by 
allele-specific oligonucleotide hybridization. It is thus 
possible to detect presymptomatic gene carriers and 
perform prenatal diagnosis of the disease. 
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